Southeastern US Specialty Pharmacy, $55M Revenue Operation

$55.2M

Revenue

$6.0M

SDE

3.5x

Multiple

Subscribe Free

Read the full deal writeup

Get Free Access

Already a member? Sign in

Full Editorial Writeup

This is a specialty pharmacy operating in the Southeastern United States, generating $55.2M in annual revenue against $6M of EBITDA. The listing is thin on detail, describing only a well-established, professionally operated pharmacy positioned as a turnkey acquisition. Specialty pharmacy typically means dispensing high-cost, complex medications for chronic and rare conditions (oncology, autoimmune, HIV, hepatitis, fertility, specialty injectables) that require special handling, patient education, insurance authorization, and ongoing adherence management.

The economics tell the real story. An 11% EBITDA margin on $55M is characteristic of the specialty pharmacy model: enormous drug pass-through revenue with thin gross spread, where the business essentially earns a dispensing margin and service fees on top of expensive inventory. This is a high-revenue, low-margin, working-capital-intensive business rather than a fat-margin retail pharmacy.

At $20.9M asking and 3.48x EBITDA, the price sits at the reasonable end for a healthcare services asset of this scale, but the multiple alone hides the diligence burden. The value here lives in payor contracts, PBM relationships, specialty drug access (limited-distribution drugs), accreditations, and the recurring patient panel on maintenance therapies. Get those right and this is a durable, defensible cash flow business.

Why we like it

Earnings quality rests on $6M of EBITDA from an essential-service business, not a hobby operation. Specialty pharmacy patients fill and refill expensive maintenance medications on a schedule, which means predictable, contract-driven dispensing volume rather than discretionary one-off sales. The buyer should verify how much of the $6M is clean, addbacks-adjusted, and free of one-time reimbursement windfalls.
Durability comes from the regulatory and contractual moat. Specialty pharmacies live or die on payor and PBM network access, URAC/ACHC accreditation, and manufacturer limited-distribution drug relationships, all of which are hard to replicate and act as barriers to new entrants. If this pharmacy holds several limited-distribution drug contracts, that is a genuine moat that protects the margin.
Market tailwinds are strong and structural. Specialty drugs now represent over half of total US pharmacy spend and continue to grow faster than traditional pharmacy as biologics and complex therapies expand. This is a rising tide business tied to chronic disease prevalence and an aging population, not a fad.
The recurring revenue profile is real. Patients on oncology, autoimmune, and other chronic specialty therapies refill month after month, creating a returning panel that compounds with net patient additions. That refill cadence is closer to a subscription than a retail transaction, which is exactly the kind of cash flow durability we want.

How to improve it

Audit and renegotiate PBM reimbursement terms within the first quarter. Specialty margins are squeezed by DIR fees and reimbursement clawbacks, so understanding the actual net-net per fill and pushing on the worst contracts can move EBITDA meaningfully without adding a single patient.
Pursue additional limited-distribution drug (LDD) contracts from manufacturers. Each new LDD adds exclusive dispensing rights and a captive patient stream, directly expanding the moat and revenue base. Map which high-value specialty drugs the pharmacy does not yet have access to and prioritize the applications.
Tighten working capital and inventory management. Specialty drugs are extremely expensive per unit, so days-in-inventory and receivables cycle time drive real cash. Implementing just-in-time ordering and faster payor collections can free up significant trapped capital in a $55M revenue book.
Build or strengthen a clinical adherence program. Higher refill adherence directly increases revenue per patient and improves payor scorecards, which in turn protects network access. A structured patient outreach and refill-reminder function pays for itself in retained fills.
Expand referral relationships with prescribing specialists and hospital systems. New patient starts flow from oncologists, rheumatologists, and specialty clinics, so a dedicated liaison function targeting these referral sources grows the panel. This is the primary growth lever in specialty pharmacy.
Evaluate adding complementary service lines such as infusion, 340B partnerships, or additional accreditations. These extend the revenue base and deepen payor and provider relationships without leaving the core competency. Each requires diligence but can materially raise the ceiling on this platform.
Systematize prior authorization and benefits investigation workflows. PA delays kill fills and frustrate prescribers; a faster, more automated PA operation increases capture rate on referred prescriptions. This is often the single biggest leak in a specialty pharmacy funnel.

Diligence notes

Scrutinize payor and PBM contract concentration and renewal terms. If a large share of revenue flows through one or two networks, a single contract loss or reimbursement cut could gut the $6M EBITDA. Confirm contract tenure, exclusivity, and any recent DIR fee or reimbursement changes.
Verify accreditations and licensure in every state where the pharmacy dispenses. Specialty pharmacies typically hold URAC and/or ACHC accreditation plus multi-state licenses, and any lapse or pending review is a material risk. Confirm all are current and transferable through a change of ownership.
Break down revenue and margin by drug and by payor. Because specialty is high revenue and thin margin, a few high-cost drugs may drive most of the profit, creating hidden concentration. Understand what happens to EBITDA if a key limited-distribution drug goes generic or loses its LDD status.
Normalize the $6M EBITDA for owner addbacks, one-time reimbursement events, and DIR fee timing. Specialty reimbursement can be lumpy, and retroactive clawbacks can distort a single year. Insist on trailing three-year financials and reconcile reported EBITDA to actual bank deposits and dispensing data.
Assess management depth and staffing, including pharmacist-in-charge and clinical team retention. Specialty pharmacy is expertise-dependent, and losing key licensed staff post-close can jeopardize both operations and accreditation. Understand the org chart, key-person dependencies, and non-competes.
Confirm the reason for sale, ownership history, and location specifics, all of which are absent from the listing. A thin description on a $20.9M asset warrants a full explanation of why the seller is exiting and what the transition plan looks like. Nail down years in operation and any prior ownership changes.

Source

Originally listed on DealStream. View original listing →